KLK4 and benign prostatic hyperplasia: KLK4 has gained support as a potential biomarker for several hormone-dependent cancers [2], and for prostate cancer specifically, in that numerous studies have found KLK4 to be significantly overexpressed in prostate carcinoma tissues compared to benign prostatic hyperplasia [6] and normal tissues [7]–[11].